DUBLIN--(BUSINESS WIRE)--The "AI-based Clinical Trials Solution Provider Market Research Report by Phase (Phase-I, Phase-II, and Phase-III), Application, End User, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
The United States AI-based Clinical Trials Solution Provider Market size was estimated at USD 1,004.79 million in 2021, USD 1,162.09 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 12.04% to reach USD 1,987.71 million by 2027.
In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward.
The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects.
It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the AI-based Clinical Trials Solution Provider Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others.
Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Company Usability Profiles:
- Antidote Technologies, Inc.
- BioSymetrics
- Deep 6 AI
- GNS Healthcare
- Google- Verily
- Halo Health Systems
- IBM Watson
- Pharmaseal
- Phesi
- Unlearn.AI, Inc.
Key Topics Covered:
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Favorable research and development initiatives by U.S private and public sector
5.1.1.2. Rising application of AI technologies in U.S pharmaceutical companies
5.1.2. Restraints
5.1.2.1. Capital intensive drug development and cumbersome process
5.1.3. Opportunities
5.1.3.1. Robust investment in clinical trials by pharmaceutical companies in U.S
5.1.3.2. Increasing inorganic growth strategies such as collaborations among key market players
5.1.4. Challenges
5.1.4.1. Lack of standard procedure from regulatory bodies for the process
5.2. Cumulative Impact of COVID-19
6. AI-based Clinical Trials Solution Provider Market, by Phase
6.1. Introduction
6.2. Phase-I
6.3. Phase-II
6.4. Phase-III
7. AI-based Clinical Trials Solution Provider Market, by Application
7.1. Introduction
7.2. Cardiovascular Diseases
7.3. Infectious Diseases
7.4. Metabolic Diseases
7.5. Neurological Diseases or Conditions
7.6. Oncology
8. AI-based Clinical Trials Solution Provider Market, by End User
8.1. Introduction
8.2. Academia
8.3. Others
8.4. Pharmaceutical Companies
9. California AI-based Clinical Trials Solution Provider Market
10. Florida AI-based Clinical Trials Solution Provider Market
11. Illinois AI-based Clinical Trials Solution Provider Market
12. New York AI-based Clinical Trials Solution Provider Market
13. Ohio AI-based Clinical Trials Solution Provider Market
14. Pennsylvania AI-based Clinical Trials Solution Provider Market
15. Texas AI-based Clinical Trials Solution Provider Market
16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.2. Market Ranking Analysis
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
17. Company Usability Profiles
For more information about this report visit https://www.researchandmarkets.com/r/k2kqto
